Skip to main content

Articles

Page 32 of 33

  1. The low-density lipoprotein receptor-related protein (LRP1) and its family members have been implicated in the pathogenesis of Alzheimer's disease. Multiple susceptibility factors converge to metabolic pathway...

    Authors: Guilian Xu, Cameron C Green, Susan E Fromholt and David R Borchelt
    Citation: Alzheimer's Research & Therapy 2012 4:12
  2. Previous work indicates that resting-state functional magnetic resonance imaging (fMRI) is sensitive to functional brain changes related to Alzheimer's disease (AD) pathology across the clinical spectrum. Cros...

    Authors: Jessica S Damoiseaux
    Citation: Alzheimer's Research & Therapy 2012 4:8
  3. Dementia, a major cause of disability and institutionalization in older people, poses a serious threat to public health and to the social and economic development of modern society. Alzheimer's disease (AD) an...

    Authors: Francesca Mangialasche, Miia Kivipelto, Alina Solomon and Laura Fratiglioni
    Citation: Alzheimer's Research & Therapy 2012 4:6
  4. Alzheimer's disease (AD) is a cognitive disorder with a number of complex neuropathologies, including, but not limited to, neurofibrillary tangles, neuritic plaques, neuronal shrinkage, hypomyelination, neuroi...

    Authors: Paul L Wood
    Citation: Alzheimer's Research & Therapy 2012 4:5
  5. Frontotemporal lobar degeneration (FTLD) is a devastating neurodegenerative disease that is the second most common form of dementia affecting individuals under age 65. The most common pathological subtype, FTL...

    Authors: Alexandra M Nicholson, Jennifer Gass, Leonard Petrucelli and Rosa Rademakers
    Citation: Alzheimer's Research & Therapy 2012 4:4
  6. Resting-state functional magnetic resonance imaging (fMRI) is emerging as an interesting biomarker for measuring connectivity of the brain in patients with Alzheimer's disease (AD). In this review, we discuss ...

    Authors: Prashanthi Vemuri, David T Jones and Clifford R Jack Jr
    Citation: Alzheimer's Research & Therapy 2012 4:2
  7. Recent epidemiologic studies have noted that risk factors for atherosclerosis (for example, diabetes mellitus, hypertension, and hyperlipidemia) are associated with increased risk of incident Alzheimer's disea...

    Authors: Helena C Chui, Ling Zheng, Bruce R Reed, Harry V Vinters and Wendy J Mack
    Citation: Alzheimer's Research & Therapy 2012 3:1
  8. Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochon...

    Authors: Rachel F Lane, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2011 3:36
  9. Patient-reported outcome (PRO) measures are used to evaluate disease and treatments in many therapeutic areas, capturing relevant aspects of the disorder not obtainable through clinician or informant report, i...

    Authors: Lori Frank, William R Lenderking, Kellee Howard and Marc Cantillon
    Citation: Alzheimer's Research & Therapy 2011 3:35
  10. Because the pathologic processes that underlie Alzheimer's disease (AD) appear to start 10 to 20 years before symptoms develop, there is currently intense interest in developing techniques to accurately predic...

    Authors: Deborah E Barnes and Sei J Lee
    Citation: Alzheimer's Research & Therapy 2011 3:33
  11. With the recent publication of new criteria for the diagnosis of preclinical Alzheimer's disease (AD), there is a need for neuropsychological tools that take premorbid functioning into account in order to dete...

    Authors: Steven D Shirk, Meghan B Mitchell, Lynn W Shaughnessy, Janet C Sherman, Joseph J Locascio, Sandra Weintraub and Alireza Atri
    Citation: Alzheimer's Research & Therapy 2011 3:32
  12. Animal models have contributed significantly to our understanding of the underlying biological mechanisms of Alzheimer's disease (AD). As a result, over 300 interventions have been investigated and reported to...

    Authors: Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney…
    Citation: Alzheimer's Research & Therapy 2011 3:28
  13. Patients with mild cognitive impairment are at an increased risk of progression to Alzheimer's disease. However, not all patients with mild cognitive impairment progress, and it is difficult to accurately iden...

    Authors: Rik Ossenkoppele, Bart NM van Berckel and Niels D Prins
    Citation: Alzheimer's Research & Therapy 2011 3:26
  14. The Relevant Outcome Scale for Alzheimer's Disease (ROSA) is a new observer rating instrument recently developed for routine medical practice. The validity and reliability of ROSA as well as sensitivity to cha...

    Authors: Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg and Frank Tennigkeit
    Citation: Alzheimer's Research & Therapy 2011 3:27
  15. [11C]Pittsburgh Compound B positron emission tomography has now been extensively used to evaluate the amyloid load in different types of dementia and has become a powerful research tool in the field of neurodegen...

    Authors: Paul Edison, Rainer Hinz and David J Brooks
    Citation: Alzheimer's Research & Therapy 2011 3:25
  16. Alzheimer's disease (AD) therapies are increasingly being tested in global clinical trials. A search of ClincalTrials.gov revealed that of 269 currently active trials, 28% are currently being conducted in the ...

    Authors: Jeffrey Cummings, Robert Reynders and Kate Zhong
    Citation: Alzheimer's Research & Therapy 2011 3:24
  17. The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibito...

    Authors: Carina Wattmo, Åsa K Wallin, Elisabet Londos and Lennart Minthon
    Citation: Alzheimer's Research & Therapy 2011 3:23
  18. Progressive language impairment is among the primary components of cognitive decline in Alzheimer's disease (AD). Because expressive and receptive language help to maintain emotional connections to caregivers ...

    Authors: Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun and Yikang Xu
    Citation: Alzheimer's Research & Therapy 2011 3:22
  19. The pathology of Alzheimer's disease (AD) is characterized by amyloid plaques (aggregates of amyloid-β (Aβ)) and neurofibrillary tangles (aggregates of tau) and is accompanied by mitochondrial dysfunction, but...

    Authors: Anne Eckert, Karen Schmitt and Jürgen Götz
    Citation: Alzheimer's Research & Therapy 2011 3:15
  20. Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's perme...

    Authors: François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy and Olivier Hermine
    Citation: Alzheimer's Research & Therapy 2011 3:16
  21. The clinical and scientific study of dementia in adults with Down syndrome led to the development of the amyloid hypothesis as a fundamental concept in Alzheimer's disease pathogenesis. The journey started wit...

    Authors: Robyn A Wallace and Arthur J Dalton
    Citation: Alzheimer's Research & Therapy 2011 3:13
  22. APOE is the strongest risk gene for sporadic Alzheimer's disease (AD) so far. Recent genome wide association studies found links for sporadic AD with CLU and CR1 involved in Aβ clearance, and PICALM affecting int...

    Authors: Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo and Pekka J Karhunen
    Citation: Alzheimer's Research & Therapy 2011 3:12
  23. Current theory suggests that β-amyloid accumulation may be an early step in the cascade that leads to cognitive impairment in Alzheimer's disease. β-Amyloid targeted positron emission tomography (PET) imaging ...

    Authors: Michael J Pontecorvo and Mark A Mintun
    Citation: Alzheimer's Research & Therapy 2011 3:11
  24. Novel compounds with potential to attenuate or stop the progression of Alzheimer's disease (AD) from its presymptomatic stage to dementia are being tested in man. The study design commonly used is the long-ter...

    Authors: René Spiegel, Manfred Berres, André R Miserez and Andreas U Monsch
    Citation: Alzheimer's Research & Therapy 2011 3:9
  25. Alzheimer's disease (AD) is widely recognized as a serious public health problem and heavy financial burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently...

    Authors: Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley and Li-Ru Zhao
    Citation: Alzheimer's Research & Therapy 2011 3:8
  26. There are more than 36 million people in the US over the age of 65, and all of them are impacted by the cognitive decline and brain atrophy associated with normal aging and dementia-causing conditions like Alz...

    Authors: Neill R Graff-Radford
    Citation: Alzheimer's Research & Therapy 2011 3:6
  27. Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheimer's disease (AD). We tested if the relationships of these biomarkers with cognitive impairment are linear or non-linear.

    Authors: Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar Laterza, William Potter and A David Smith
    Citation: Alzheimer's Research & Therapy 2011 3:5
  28. Alzheimer disease (AD) is a devastating neurodegenerative disease affecting 1 in 68 in the population. An arbitrary cutoff 65 years as the age of onset to distinguish between early- and late-onset AD has been ...

    Authors: Kinga Szigeti and Rachelle S Doody
    Citation: Alzheimer's Research & Therapy 2011 3:4
  29. Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and mole...

    Authors: Randall J Bateman, Paul S Aisen, Bart De Strooper, Nick C Fox, Cynthia A Lemere, John M Ringman, Stephen Salloway, Reisa A Sperling, Manfred Windisch and Chengjie Xiong
    Citation: Alzheimer's Research & Therapy 2011 3:1
  30. Inhibition of gamma-secretase presents a direct target for lowering Aβ production in the brain as a therapy for Alzheimer's disease (AD). However, gamma-secretase is known to process multiple substrates in add...

    Authors: Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui…
    Citation: Alzheimer's Research & Therapy 2010 2:36